Last updated: October 6, 2026
Fosinopril sodium and hydrochlorothiazide is a mature, largely commoditized antihypertensive combination. Its commercial value is concentrated in low-cost generic prescriptions rather than branded sales, new indications, or patent-protected pricing. The original brand, Monopril HCT, no longer has meaningful U.S. exclusivity, and no material biosimilar issue exists because the product is a small-molecule drug. Financial performance is likely stable to declining at the molecule level, with limited upside outside supply optimization, contracting, and selected international markets.
What is fosinopril sodium and hydrochlorothiazide used for?
Fosinopril sodium and hydrochlorothiazide combines an angiotensin-converting enzyme, or ACE, inhibitor with a thiazide diuretic.
| Component |
Pharmacologic role |
Commercial relevance |
| Fosinopril sodium |
ACE inhibitor; converted to the active metabolite fosinoprilat |
Controls vasoconstriction and aldosterone signaling |
| Hydrochlorothiazide |
Thiazide diuretic |
Promotes sodium and water excretion |
| Combination |
Fixed-dose antihypertensive |
Improves convenience for patients requiring two mechanisms |
The FDA-approved indication is treatment of hypertension in patients who require combination therapy. The product is not positioned as a first-line treatment for every patient. Current hypertension guidelines generally prioritize evidence-based first-line agents, including thiazide-type diuretics, ACE inhibitors, angiotensin-receptor blockers, and calcium-channel blockers, with combination therapy used when blood-pressure control requires more than one drug.[1]
Fosinopril has a distinctive hepatic conversion pathway and dual renal and nonrenal elimination. That feature can be clinically relevant in patients with impaired renal function, but it has not created a durable commercial advantage over widely used alternatives such as lisinopril, losartan, or valsartan combinations.[2]
What brands and dosage forms are associated with fosinopril hydrochlorothiazide?
The original U.S. brand was Monopril HCT, marketed by Bristol-Myers Squibb. The product was supplied as oral tablets, principally in fixed-dose strengths combining fosinopril sodium with hydrochlorothiazide.
Commonly referenced strengths include:
| Strength |
Fosinopril sodium |
Hydrochlorothiazide |
| Lower strength |
10 mg |
12.5 mg |
| Higher strength |
20 mg |
12.5 mg |
Generic labeling and product availability have varied by manufacturer and jurisdiction. FDA labeling identifies the combination as an oral tablet for hypertension, with dosage adjustment based on the patient’s response and prior exposure to each component.[3]
The formulation is relatively simple compared with extended-release, inhaled, injectable, or biologic products. This reduces manufacturing complexity and lowers the barrier to generic replication.
What is the FDA regulatory status of fosinopril sodium and hydrochlorothiazide?
Fosinopril hydrochlorothiazide was approved through the conventional new-drug pathway and subsequently became subject to abbreviated new drug applications, or ANDAs, after loss of branded exclusivity.
The regulatory profile is mature:
- The product is a prescription oral tablet.
- The active ingredients are well established.
- Generic approval depends primarily on pharmaceutical equivalence and bioequivalence.
- No biologic-license application or biosimilar pathway applies.
- No pediatric exclusivity or orphan-drug framework is associated with the combination.
- FDA risk management is based mainly on class warnings and routine labeling.
ACE-inhibitor class risks include fetal toxicity, angioedema, hyperkalemia, hypotension, and renal-function changes. Hydrochlorothiazide can contribute to electrolyte abnormalities, volume depletion, photosensitivity, hyperuricemia, and glucose or lipid changes.[3]
The principal regulatory risk is therefore not clinical novelty but manufacturing compliance, product availability, and continued commercial viability.
What is the Orange Book status of Monopril HCT?
Monopril HCT has no commercially important period of remaining U.S. market exclusivity. The relevant branded patents and regulatory exclusivities expired years ago, allowing generic competition.
The Orange Book remains the primary FDA source for determining listed patents, therapeutic-equivalence codes, and reference-listed-drug status.[4] For a mature product such as fosinopril sodium and hydrochlorothiazide, the practical Orange Book questions are:
- Whether the branded reference product remains actively marketed.
- Whether generic products retain active approval.
- Whether any patent listing remains relevant to ANDA certification.
- Whether the reference-listed drug has been discontinued or moved into a limited-availability category.
The combination does not have a current patent profile comparable to newer cardiovascular products. Any remaining patent issue would be product-specific and would need confirmation against the current Orange Book rather than inferred from the historical brand record.
When does fosinopril hydrochlorothiazide lose exclusivity?
Fosinopril hydrochlorothiazide lost U.S. market exclusivity in the early generic era. The individual active ingredient, fosinopril, was approved in the early 1990s, and the fixed-dose combination followed during the same broad product cycle. The original branded exclusivity period has long ended.
Patent and exclusivity timeline
| Event |
Approximate period |
Commercial effect |
| Fosinopril introduced |
Early 1990s |
Branded ACE-inhibitor launch |
| Monopril HCT introduced |
Early-to-mid 1990s |
Fixed-dose combination expansion |
| Original patent and regulatory exclusivity period |
Late 1990s to early 2000s |
Transition toward generic competition |
| Generic approvals |
Subsequent years |
Price erosion and increased substitution |
| Current status |
Mature generic market |
Limited pricing power and low differentiation |
The exact expiration date for any historical patent depends on the patent family, terminal disclaimers, regulatory extensions, and jurisdiction. No current U.S. commercial thesis depends on a surviving composition-of-matter or formulation patent.
What patents protect fosinopril sodium and hydrochlorothiazide?
The original intellectual-property estate covered the ACE-inhibitor chemistry, pharmaceutical compositions, and fixed-dose treatment concepts. Those rights are now historical rather than commercially blocking in the United States.
Composition and active-ingredient patents
Fosinopril is a prodrug of fosinoprilat and was protected by early chemical and pharmaceutical patents associated with Bristol-Myers Squibb. These patents supported the original Monopril franchise but are expired.
Formulation patents
The fixed-dose combination was protected primarily through conventional pharmaceutical composition and formulation claims. The product does not require a specialized delivery system, depot technology, device, or complex release mechanism. That limits the ability of a manufacturer to establish a durable secondary patent estate.
Method-of-use patents
The main use is treatment of hypertension. Antihypertensive method-of-use claims are generally broad and difficult to sustain as commercially meaningful barriers after the underlying composition and product patents expire. No current U.S. method-of-use patent is widely recognized as a material barrier to generic substitution for this combination.
Manufacturing and process protection
Manufacturing know-how may still provide operational value. Relevant areas include:
- Control of impurity formation.
- Stability of the ACE-inhibitor component.
- Tablet compression and uniformity.
- Packaging against moisture and degradation.
- Reliable sourcing of hydrochlorothiazide and fosinopril intermediates.
These measures can protect cost position and supply continuity, but they usually do not prevent an approved generic competitor from entering.
How many patents cover fosinopril hydrochlorothiazide?
The historical product was associated with multiple patents and patent-family filings, but the economically relevant number of active U.S. blocking patents is effectively zero for ordinary generic tablets. Patent-family counts can overstate protection because one invention may generate U.S. continuations, foreign counterparts, and expired claims.
A current freedom-to-operate review would focus on:
- Active Orange Book listings.
- Patent term adjustments or extensions.
- Litigation records involving ANDA applicants.
- Active foreign patents in target markets.
- Process patents that may affect manufacturing routes.
For commercial planning, the estate is weak compared with recently launched small molecules that use polymorph, crystalline-form, metabolite, formulation, or device patents to extend exclusivity.
Which companies compete with fosinopril hydrochlorothiazide?
Competition comes from both therapeutic substitutes and generic manufacturers.
Therapeutic substitutes
| Combination |
Competitive position |
| Lisinopril/hydrochlorothiazide |
Stronger U.S. prescribing familiarity and broader generic availability |
| Enalapril/hydrochlorothiazide |
Established ACE-inhibitor alternative |
| Losartan/hydrochlorothiazide |
Major ARB/thiazide alternative; avoids ACE-inhibitor cough |
| Valsartan/hydrochlorothiazide |
Branded and generic ARB combination |
| Irbesartan/hydrochlorothiazide |
Established ARB combination |
| Amlodipine-based combinations |
Compete where calcium-channel blockade is preferred |
Lisinopril/hydrochlorothiazide and losartan/hydrochlorothiazide are usually stronger commercial comparators. They have broader prescriber familiarity, extensive generic supply, and greater representation in treatment algorithms.
Generic manufacturers
Generic availability can include products from large multinational and regional manufacturers, depending on the market. The competitive set has historically included companies such as Teva, Mylan, Apotex, Lupin, and other ANDA holders. The active supplier list changes as firms discontinue low-margin products or transfer approvals.
Because the drug is old and price-sensitive, manufacturers compete primarily on:
- Reliable API sourcing.
- Manufacturing cost.
- Wholesaler contracts.
- Pharmacy benefit manager access.
- Inventory availability.
- Ability to avoid supply interruptions.
What is the market size and revenue exposure?
Standalone revenue for fosinopril sodium and hydrochlorothiazide is generally not disclosed by public companies. Large manufacturers report cardiovascular or generic portfolios in aggregate, rather than reporting revenue for a low-volume fixed-dose combination.
The financial profile can be characterized as follows:
| Financial factor |
Assessment |
| Brand revenue |
Minimal or absent in the United States |
| Generic revenue |
Low per-unit value; dependent on prescription volume |
| Gross margin |
Vulnerable to price competition and manufacturing costs |
| Growth potential |
Low |
| Regulatory investment |
Limited unless tied to supply or portfolio strategy |
| Litigation value |
Low because no meaningful exclusivity remains |
| Licensing value |
Generally low outside regional commercialization rights |
| Supply-chain value |
More important than patent value |
The molecule may generate modest aggregate revenue across international markets, hospital channels, and chronic-care formularies. It is unlikely to represent a material revenue driver for a diversified pharmaceutical company unless the company has a large generic portfolio or a temporary supply advantage.
Revenue trajectory
The likely lifecycle trajectory is:
- Launch phase: Premium branded pricing and physician promotion.
- Generic-entry phase: Rapid decline in price and branded share.
- Mature phase: Stable but low-value prescription demand.
- Late mature phase: Revenue determined by supply continuity, tender wins, and portfolio rationalization.
Volume may remain relatively stable because hypertension is a chronic condition. Revenue can still decline as reimbursement pressure reduces average selling prices.
What generic entry risks exist?
Generic entry is no longer a future risk for this product. It is the established market condition.
The relevant risks are operational:
- A new entrant can intensify price competition.
- A supplier exit can create temporary shortages but may not support durable price increases.
- API concentration can expose manufacturers to cost inflation.
- State and federal purchasing programs can compress margins.
- Pharmacy substitution favors products with dependable supply and low acquisition cost.
- A competitor with a lower-cost manufacturing route can win contracts without owning superior patents.
For an originator, the risk is loss of brand relevance. For a generic manufacturer, the risk is that market participation produces inadequate returns after quality, regulatory, distribution, and pharmacovigilance costs.
What patent litigation and Paragraph IV challenges affect the product?
No current high-value U.S. Paragraph IV litigation campaign is associated with fosinopril sodium and hydrochlorothiazide. Paragraph IV challenges were relevant during the transition from branded exclusivity to generic entry, but that period is historical.
The absence of active litigation is commercially important. It indicates:
- No meaningful patent barrier remains.
- Generic approval does not depend on resolving a major current dispute.
- Settlement economics are limited.
- The product is unlikely to generate material litigation-based delay value.
Any current litigation would more likely involve manufacturing, supply, contract, product liability, or distribution issues than core patent exclusivity.
What licensing deals involve fosinopril hydrochlorothiazide?
No major recent licensing transaction is widely associated with the combination. Historical commercialization depended on originator marketing and later generic approvals, distribution arrangements, and product transfers.
Potential deal value is limited because:
- The product has no meaningful exclusivity.
- Switching costs are low.
- Multiple substitute therapies exist.
- The product requires limited formulation differentiation.
- Revenue is difficult to scale without established distribution.
A regional licensing or authorized-generic arrangement could still make sense where local registration, tender access, or manufacturing capacity has value. Such deals would be commercial-supply transactions rather than high-value innovation licenses.
How strong is the patent estate compared with competing antihypertensives?
Fosinopril hydrochlorothiazide has a weak current patent estate.
| Product |
Current patent strength |
Generic competition |
Commercial outlook |
| Fosinopril/HCTZ |
Very low |
Established |
Mature, low-margin |
| Lisinopril/HCTZ |
Very low |
Extensive |
Higher-volume generic category |
| Losartan/HCTZ |
Very low |
Extensive |
Strong therapeutic substitution |
| Newer branded antihypertensive combinations |
Variable |
Limited or delayed |
Greater pricing power if protected |
Its competitive weakness is not clinical failure. It is the combination of old chemistry, broad substitution, limited differentiation, and low reimbursement value.
What is the outlook for fosinopril sodium and hydrochlorothiazide?
The five-year outlook is stable to declining in nominal revenue, with prescription demand sustained by chronic hypertension treatment but constrained by generic pricing.
The most plausible commercial scenarios are:
- Base case: Continued low-volume generic sales with gradual price erosion.
- Upside case: Temporary supply disruption among competitors or a regional tender win.
- Downside case: Manufacturer discontinuation caused by low margins, compliance costs, or API constraints.
- Strategic case: Inclusion in a broader low-cost cardiovascular portfolio rather than standalone investment.
No meaningful revenue reacceleration is expected from patent extension, new indications, pediatric exclusivity, or formulation innovation.
Key Takeaways
- Fosinopril sodium and hydrochlorothiazide is a mature generic antihypertensive combination.
- Monopril HCT has no meaningful remaining U.S. exclusivity.
- The active U.S. patent estate is not a material barrier to generic entry.
- No biosimilar risk applies because the product is a small molecule.
- Standalone revenue is not generally disclosed and is likely modest.
- Financial performance depends on volume, supply reliability, tenders, and manufacturing cost.
- Lisinopril/hydrochlorothiazide and losartan/hydrochlorothiazide are stronger commercial substitutes.
- Current business risk is operational and pricing-related, not patent-litigation-related.
- Licensing value is limited to regional distribution, supply, and portfolio transactions.
- The long-term outlook is low-margin stability followed by gradual commercial attrition.
FAQs
Is fosinopril hydrochlorothiazide still commercially available?
Availability depends on country, manufacturer, and wholesaler inventory. Generic approvals and product listings can persist even when individual manufacturers discontinue distribution.
Is fosinopril hydrochlorothiazide stronger than lisinopril hydrochlorothiazide?
Neither combination is universally stronger. Response depends on dose, adherence, renal function, tolerability, and patient-specific blood-pressure requirements.
Does fosinopril hydrochlorothiazide have a biosimilar competitor?
No. Biosimilars apply to biological products. Fosinopril hydrochlorothiazide is a chemically synthesized small-molecule tablet and competes through generic equivalence.
Can a generic manufacturer obtain new patents on fosinopril hydrochlorothiazide?
A manufacturer could pursue patents on a genuinely novel formulation, manufacturing process, or use. Such patents would need to satisfy novelty, non-obviousness, written-description, and enablement requirements and would not automatically block ordinary generic tablets.
Is fosinopril hydrochlorothiazide attractive for pharmaceutical investment?
As a standalone asset, it has limited investment appeal. It may have value within a broader generic portfolio where procurement scale, manufacturing efficiency, and distribution infrastructure improve margins.
References
-
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
-
U.S. Food and Drug Administration. (n.d.). Fosinopril sodium prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Fosinopril sodium and hydrochlorothiazide prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
